1. Home
  2. PRTA vs HOND Comparison

PRTA vs HOND Comparison

Compare PRTA & HOND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTA
  • HOND
  • Stock Information
  • Founded
  • PRTA 2012
  • HOND 2024
  • Country
  • PRTA Ireland
  • HOND United States
  • Employees
  • PRTA N/A
  • HOND N/A
  • Industry
  • PRTA Biotechnology: Pharmaceutical Preparations
  • HOND
  • Sector
  • PRTA Health Care
  • HOND
  • Exchange
  • PRTA Nasdaq
  • HOND NYSE
  • Market Cap
  • PRTA 346.4M
  • HOND 334.9M
  • IPO Year
  • PRTA N/A
  • HOND 2024
  • Fundamental
  • Price
  • PRTA $6.41
  • HOND $10.89
  • Analyst Decision
  • PRTA Buy
  • HOND
  • Analyst Count
  • PRTA 9
  • HOND 0
  • Target Price
  • PRTA $27.67
  • HOND N/A
  • AVG Volume (30 Days)
  • PRTA 1.7M
  • HOND 361.1K
  • Earning Date
  • PRTA 08-07-2025
  • HOND 01-01-0001
  • Dividend Yield
  • PRTA N/A
  • HOND N/A
  • EPS Growth
  • PRTA N/A
  • HOND N/A
  • EPS
  • PRTA N/A
  • HOND 0.20
  • Revenue
  • PRTA $137,935,000.00
  • HOND N/A
  • Revenue This Year
  • PRTA N/A
  • HOND N/A
  • Revenue Next Year
  • PRTA $122.02
  • HOND N/A
  • P/E Ratio
  • PRTA N/A
  • HOND $53.55
  • Revenue Growth
  • PRTA 54.55
  • HOND N/A
  • 52 Week Low
  • PRTA $4.32
  • HOND $9.90
  • 52 Week High
  • PRTA $25.42
  • HOND $12.24
  • Technical
  • Relative Strength Index (RSI)
  • PRTA 57.61
  • HOND N/A
  • Support Level
  • PRTA $5.96
  • HOND N/A
  • Resistance Level
  • PRTA $6.77
  • HOND N/A
  • Average True Range (ATR)
  • PRTA 0.36
  • HOND 0.00
  • MACD
  • PRTA 0.14
  • HOND 0.00
  • Stochastic Oscillator
  • PRTA 75.80
  • HOND 0.00

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

About HOND HCM II ACQUISITION CORP

HCM II Acquisition Corp is a blank check company.

Share on Social Networks: